Choose Your Country or Region

Atenolol

Name: Atenolol
Brand: Selleck Chemicals
SKU: S4817
Rating: 5 (2 reviews)

Synonyms: Tenormin, Normiten, Blokium

Catalog No.S4817 Purity: 99.88%

Atenolol (Tenormin, Normiten, Blokium) is a selective β1 receptor antagonist with log Kd values of −6.66±0.05, −5.99±0.14, −4.11±0.07 for binding to the human β1-, β2- and β3-adrenoceptors.

Atenolol Chemical Structure

CAS: 29122-68-7

Selleck's Atenolol has been cited by 2 publications

Purity & Quality Control

Batch: S481701 DMSO] 53 mg/mL] false] Ethanol] 53 mg/mL] false] Water] 35 mg/mL] false Purity: 99.88%

99.88

Other Adrenergic Receptor Products

Related compound libraries

Choose Selective Adrenergic Receptor Inhibitors

Biological Activity

Description

Targets

β1 receptor ^[1] (Cell-free assay)	β2 receptor ^[1] (Cell-free assay)
0.25 μM(Kd)	1 μM(Kd)

In Vivo
In vivo	In clinical pharmacokinetics studies, atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. After oral administration elimination half life of atenolol is calculated from 6 to 9 h. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia while no correlation is found between plasma levels of atenolol and blood pressure lowering activity of the drug^[3].
Animal Research	Animal Models	spontaneously hypertensive rats (SHR), Wistar-Kyoto (WKY)
	Dosages	20 mg/kg
	Administration	s.c.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT04224675	Unknown status	Aneurysm	Onassis Cardiac Surgery Centre	March 7 2020	Not Applicable
NCT01719367	Completed	Atrial Fibrillation	Vanderbilt University Medical Center	January 2013	Not Applicable
NCT01361087	Withdrawn	Marfan Syndrome	Ann & Robert H Lurie Children''s Hospital of Chicago\|Johns Hopkins University	April 2011	Phase 3
NCT01132768	Terminated	Essential Hypertension\|Carotid Plaque	Daiichi Sankyo Europe GmbH a Daiichi Sankyo Company\|Daiichi Sankyo Inc.	May 2010	Phase 4

References

Chemical lnformation & Solubility

Molecular Weight	266.34	Formula	C₁₄H₂₂N₂O₃
CAS No.	29122-68-7	SDF	--
Smiles	CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 53 mg/mL ( (198.99 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 53 mg/mL

Water : 35 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):